Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Accumulated Expenses (2020 - 2025)

RxSight's Accumulated Expenses history spans 6 years, with the latest figure at $19.8 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 2.77% year-over-year to $19.8 million; the TTM value through Dec 2025 reached $19.8 million, down 2.77%, while the annual FY2025 figure was $19.8 million, 2.77% down from the prior year.
  • Accumulated Expenses reached $19.8 million in Q4 2025 per RXST's latest filing, up from $17.6 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $20.4 million in Q4 2024 to a low of $4.8 million in Q2 2021.
  • Average Accumulated Expenses over 5 years is $12.4 million, with a median of $12.7 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: soared 88.28% in 2021, then fell 2.77% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $7.9 million in 2021, then surged by 61.24% to $12.7 million in 2022, then rose by 20.26% to $15.2 million in 2023, then surged by 33.59% to $20.4 million in 2024, then decreased by 2.77% to $19.8 million in 2025.
  • Per Business Quant, the three most recent readings for RXST's Accumulated Expenses are $19.8 million (Q4 2025), $17.6 million (Q3 2025), and $15.9 million (Q2 2025).